7746-29-4

Basic information

• Product Name: 6-METHOXY-3-METHYL-1H-INDAZOLE
• Synonyms: 6-METHOXY-3-METHYL-1H-INDAZOLE;3-METHYL-6-METHOXY 1H-INDAZOLE
• CAS NO: 7746-29-4
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Mol File: 7746-29-4.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-METHOXY-3-METHYL-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-3-METHYL-1H-INDAZOLE(7746-29-4)
• EPA Substance Registry System: 6-METHOXY-3-METHYL-1H-INDAZOLE(7746-29-4)

Safety Data

• Hazardous Substances Data: 7746-29-4(Hazardous Substances Data)

Usage

General Description

6-Methoxy-3-methyl-1H-indazole is a chemical compound with the molecular formula C9H10N2O. It is a derivative of indazole, a bicyclic aromatic heterocycle that is commonly used in the synthesis of pharmaceuticals and other organic compounds. 6-Methoxy-3-methyl-1H-indazole is a white to light yellow crystalline solid that is soluble in organic solvents. It has been studied for its potential pharmacological properties, including its antiviral and anti-inflammatory activities. Additionally, this chemical has been investigated as a potential building block in the synthesis of bioactive compounds and in chemical research.

Upstream product

• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 

Downstream Products

• 201286-96-6 3-methyl-indazole-6-carboxylic acid 
• 848468-06-4 C₂₇H₃₆N₂O₅Si 
• 848468-05-3 C₂₇H₃₈N₂O₅Si 
• 691905-46-1 C₁₆H₁₄N₂O₃ 
• 518987-37-6 6-methoxy-1H-indazole-3-carbaldehyde 
• 201286-99-9 3-methyl-1H-indazol-6-ol 
• 691900-70-6 tert-butyl-6-methoxy-3-methyl-1-indazole-carboxylate 
• 362512-26-3 6-Benzyloxy-3-methyl-1H-indazole 

Relevant articles and documents

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.